Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice.

Giles K, Berry DB, Condello C, Dugger BN, Li Z, Oehler A, Bhardwaj S, Elepano M, Guan S, Silber BM, Olson SH, Prusiner SB.

J Pharmacol Exp Ther. 2016 Sep;358(3):537-47. doi: 10.1124/jpet.116.235556. Epub 2016 Jun 17.

2.

Different 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains.

Giles K, Berry DB, Condello C, Hawley RC, Gallardo-Godoy A, Bryant C, Oehler A, Elepano M, Bhardwaj S, Patel S, Silber BM, Guan S, DeArmond SJ, Renslo AR, Prusiner SB.

J Pharmacol Exp Ther. 2015 Oct;355(1):2-12. doi: 10.1124/jpet.115.224659. Epub 2015 Jul 29.

3.

Novel compounds lowering the cellular isoform of the human prion protein in cultured human cells.

Silber BM, Gever JR, Rao S, Li Z, Renslo AR, Widjaja K, Wong C, Giles K, Freyman Y, Elepano M, Irwin JJ, Jacobson MP, Prusiner SB.

Bioorg Med Chem. 2014 Mar 15;22(6):1960-72. doi: 10.1016/j.bmc.2014.01.001. Epub 2014 Jan 9.

4.

Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.

Silber BM, Gever JR, Li Z, Gallardo-Godoy A, Renslo AR, Widjaja K, Irwin JJ, Rao S, Jacobson MP, Ghaemmaghami S, Prusiner SB.

Bioorg Med Chem. 2013 Dec 15;21(24):7999-8012. doi: 10.1016/j.bmc.2013.09.022. Epub 2013 Sep 18.

5.

Optimization of Arylamides as Novel, Potent and Brain-penetrant Antiprion Lead Compounds.

Li Z, Rao S, Gever JR, Widjaja K, Prusiner SB, Silber BM.

ACS Med Chem Lett. 2013 Jul 11;4(7):647-650.

6.

Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice.

Lu D, Giles K, Li Z, Rao S, Dolghih E, Gever JR, Geva M, Elepano ML, Oehler A, Bryant C, Renslo AR, Jacobson MP, Dearmond SJ, Silber BM, Prusiner SB.

J Pharmacol Exp Ther. 2013 Nov;347(2):325-38. doi: 10.1124/jpet.113.205799. Epub 2013 Aug 21.

7.

Discovery and Preliminary SAR of Arylpiperazines as Novel, Brainpenetrant Antiprion Compounds.

Li Z, Gever J, Rao S, Widjaja K, Prusiner SB, Silber BM.

ACS Med Chem Lett. 2013 Apr 11;4(4):397-401.

8.

2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease.

Li Z, Silber BM, Rao S, Gever JR, Bryant C, Gallardo-Godoy A, Dolghih E, Widjaja K, Elepano M, Jacobson MP, Prusiner SB, Renslo AR.

ChemMedChem. 2013 May;8(5):847-57. doi: 10.1002/cmdc.201300007. Epub 2013 Mar 18.

9.

Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.

Silber BM, Rao S, Fife KL, Gallardo-Godoy A, Renslo AR, Dalvie DK, Giles K, Freyman Y, Elepano M, Gever JR, Li Z, Jacobson MP, Huang Y, Benet LZ, Prusiner SB.

Pharm Res. 2013 Apr;30(4):932-50. doi: 10.1007/s11095-012-0912-4. Epub 2013 Feb 16.

10.

Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity.

Thompson MJ, Louth JC, Ferrara S, Jackson MP, Sorrell FJ, Cochrane EJ, Gever J, Baxendale S, Silber BM, Roehl HH, Chen B.

Eur J Med Chem. 2011 Sep;46(9):4125-32. doi: 10.1016/j.ejmech.2011.06.013. Epub 2011 Jun 17.

PMID:
21726921
11.

2-Aminothiazoles as therapeutic leads for prion diseases.

Gallardo-Godoy A, Gever J, Fife KL, Silber BM, Prusiner SB, Renslo AR.

J Med Chem. 2011 Feb 24;54(4):1010-21. doi: 10.1021/jm101250y. Epub 2011 Jan 19.

12.

Driving drug discovery: the fundamental role of academic labs.

Silber BM.

Sci Transl Med. 2010 May 5;2(30):30cm16. doi: 10.1126/scitranslmed.3000169.

PMID:
20445199
13.

Toward a 21st-century health care system: recommendations for health care reform.

Arrow K, Auerbach A, Bertko J, Brownlee S, Casalino LP, Cooper J, Crosson FJ, Enthoven A, Falcone E, Feldman RC, Fuchs VR, Garber AM, Gold MR, Goldman D, Hadfield GK, Hall MA, Horwitz RI, Hooven M, Jacobson PD, Jost TS, Kotlikoff LJ, Levin J, Levine S, Levy R, Linscott K, Luft HS, Mashal R, McFadden D, Mechanic D, Meltzer D, Newhouse JP, Noll RG, Pietzsch JB, Pizzo P, Reischauer RD, Rosenbaum S, Sage W, Schaeffer LD, Sheen E, Silber BM, Skinner J, Shortell SM, Thier SO, Tunis S, Wulsin L Jr, Yock P, Nun GB, Bryan S, Luxenburg O, van de Ven WP.

Ann Intern Med. 2009 Apr 7;150(7):493-5. Epub 2009 Mar 2.

PMID:
19258550
14.

CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.

McElroy S, Sachse C, Brockmoller J, Richmond J, Lira M, Friedman D, Roots I, Silber BM, Milos PM.

AAPS PharmSci. 2000;2(4):E33.

15.

The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P.

J Pharmacol Exp Ther. 1997 Oct;283(1):46-58.

PMID:
9336307
16.

A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography.

Potchoiba MJ, Tensfeldt TG, Nocerini MR, Silber BM.

J Pharmacol Exp Ther. 1995 Feb;272(2):953-62.

PMID:
7853213
17.

Pharmacokinetics of tiqueside (beta-tigogenin cellobioside) in dogs, rats, rabbits, and monkeys.

Inskeep PB, Connolly AG, Cole MJ, Luther EW, Biehl ML, Marzetta CA, Savoy YE, Silber BM.

J Pharm Sci. 1995 Jan;84(1):12-4.

PMID:
7714734
19.

Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration.

Cheung WK, Greene DS, Kuye O, Shin K, Tonelli AP, Houston A, Hibberd M, Faulkner RD, Silber BM.

J Chemother. 1989 Jul;1(4 Suppl):507-8. No abstract available.

PMID:
16312506
20.

Pharmacokinetics of YTR830H in healthy human subjects.

Cheung WK, Greene DS, Kuye O, Smith MP, Holder A, Fernandez P, Houston A, Faulkner RD, Silber BM.

J Chemother. 1989 Jul;1(4 Suppl):505-6. No abstract available.

PMID:
16312505
21.

Bioequivalency of oral suspension formulations of cefixime.

Faulkner RD, Sia LL, Barone JS, Forbes SJ, Silber BM.

Biopharm Drug Dispos. 1989 Mar-Apr;10(2):205-11.

PMID:
2706319
22.

Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine.

Cheung WK, Sia LL, Woodward DL, Graveline JF, Desjardins RE, Yacobi A, Silber BM.

J Clin Pharmacol. 1988 Nov;28(11):1001-7.

PMID:
3243913
23.

Pharmacokinetic evaluation of a sustained-release formulation of trihexyphenidyl in healthy volunteers.

Cheung WK, Stravinski SS, Engel SI, Sia LL, Yacobi A, Silber BM.

J Pharm Sci. 1988 Sep;77(9):748-50.

PMID:
3225767
24.

Absolute bioavailability of cefixime in man.

Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ, Weiss AI, Yacobi A, Silber BM.

J Clin Pharmacol. 1988 Aug;28(8):700-6.

PMID:
3216036
25.

Pharmacokinetics of cefixime in the young and elderly.

Faulkner RD, Bohaychuk W, Lanc RA, Haynes JD, Desjardins RE, Yacobi A, Silber BM.

J Antimicrob Chemother. 1988 Jun;21(6):787-94.

PMID:
3410802
26.

In vitro protein binding interaction studies involving cefixime.

Bialer M, Wu WH, Faulkner RD, Silber BM, Yacobi A.

Biopharm Drug Dispos. 1988 May-Jun;9(3):315-20.

PMID:
3395672
27.

Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog.

Wu WH, Henderson BM, Lanc R, Garnes D, Yacobi A, Silber BM.

Drug Metab Dispos. 1988 Mar-Apr;16(2):222-7.

PMID:
2898337
28.

Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers.

Cheung WK, Woodward DL, Shin K, Hibberd M, Pearse S, Desjardins RE, Yacobi A, Silber BM.

Int J Clin Pharmacol Res. 1988;8(5):299-305.

PMID:
3229870
29.

The pharmacokinetics of cefixime in the fasted and fed state.

Faulkner RD, Bohaychuk W, Haynes JD, Desjardins RE, Yacobi A, Silber BM.

Eur J Clin Pharmacol. 1988;34(5):525-8.

PMID:
3203716
30.

Changes in tissue concentrations of 14C-doxorubicin caused by mitoxantrone, mithramycin A and vinblastine in the rat.

Cheung WK, Aiache M, Yacobi A, Silber BM.

Res Commun Chem Pathol Pharmacol. 1988 Jan;59(1):61-8.

PMID:
2965402
31.

Determination of cefixime in biological samples by reversed-phase high-performance liquid chromatography.

Falkowski AJ, Look ZM, Noguchi H, Silber BM.

J Chromatogr. 1987 Nov 27;422:145-52.

PMID:
3437003
32.

Pharmacokinetic profile of cefixime in man.

Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM.

Pediatr Infect Dis J. 1987 Oct;6(10):963-70.

PMID:
3696837
34.

Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state.

Faulkner RD, Bohaychuk W, Desjardins RE, Look ZM, Haynes JD, Weiss AI, Silber BM.

J Clin Pharmacol. 1987 Oct;27(10):807-12.

PMID:
3429686
35.

Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.

Bialer M, Wu WH, Look ZM, Silber BM, Yacobi A.

Res Commun Chem Pathol Pharmacol. 1987 Apr;56(1):21-32.

PMID:
3589152
36.

Dose-dependent pharmacokinetics of a new oral cephalosporin, cefixime, in the dog.

Bialer M, Batra VK, Morrison JA, Silber BM, Look ZM, Yacobi A.

Pharm Res. 1987 Feb;4(1):33-7.

PMID:
3508527
37.

The relationship between drug input and mean residence time in the body.

Bialer M, Look ZM, Silber BM, Yacobi A.

Biopharm Drug Dispos. 1986 Nov-Dec;7(6):577-83.

PMID:
3828487
38.

Nonlinear formation of propranolol metabolites in dogs after portacaval transpositions.

Lo MW, Pond SM, Effeney DJ, Silber BM, Riegelman S, Tozer TN.

J Pharmacokinet Biopharm. 1984 Aug;12(4):401-12.

PMID:
6527232
39.
40.

Dose-dependent elimination of propranolol and its major metabolites in humans.

Silber BM, Holford NH, Riegelman S.

J Pharm Sci. 1983 Jul;72(7):725-32. No abstract available.

PMID:
6886977
41.

Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition.

Lo MW, Effeney DJ, Pond SM, Silber BM, Riegelman S.

J Pharmacol Exp Ther. 1982 May;221(2):512-5.

PMID:
7077541
42.

A technique to study hepatic and intestinal drug metabolism separately in the dog.

Effeney DJ, Pond SM, Lo MW, Silber BM, Riegelman S.

J Pharmacol Exp Ther. 1982 May;221(2):507-11.

PMID:
7077540

Supplemental Content

Loading ...
Support Center